Paul J Martin

List of Publications by Year
in descending order

177 papers	24,519 citations	9786 73 h-index	7348 152 g-index
177 all docs	177 docs citations	177 times ranked	15822 citing authors

#	Article	IF	Citations
1	Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation. Blood Advances, 2022, , .	5.2	0
2	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology, 2022, 40, 1174-1185.	1.6	36
3	Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. Transplantation and Cellular Therapy, 2022, , .	1.2	5
4	Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Advances, 2022, , .	5.2	1
5	Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia, 2022, 36, 1907-1915.	7.2	7
6	Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. Frontiers in Immunology, 2022, 13, .	4.8	1
7	Sitagliptin to Prevent Acute Graft-versus-Host Disease. New England Journal of Medicine, 2021, 384, 70-71.	27.0	5
8	IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice. Nature Communications, 2021, 12, 805.	12.8	14
9	The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. Transplantation and Cellular Therapy, 2021, 27, 448-451.	1.2	13
10	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 452-466.	1.2	24
11	Tolerogenic antiâ€"IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. Blood, 2021, 137, 2243-2255.	1.4	12
12	MR Imaging Findings in a Neonate With COVID -19-Associated Encephalitis. Pediatric Neurology, 2021, 119, 48-49.	2.1	15
13	Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. American Journal of Transplantation, 2021, 21, 3538-3549.	4.7	9
14	Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 616.e1-616.e6.	1.2	20
15	Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Blood, 2021, 138, 1628-1636.	1.4	7
16	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 545-557.	1.2	72
17	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	1.2	21
18	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplantation and Cellular Therapy, 2021, 27, 729-737.	1.2	29

#	Article	IF	Citations
19	Genetic Variants Associated with Inflammatory Bowel Disease and Gut Graft-versus-host Disease. Blood Advances, 2021, 5, 4456-4464.	5.2	1
20	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. Blood Advances, 2021, 5, 4549-4559.	5.2	8
21	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 759.e1-759.e8.	1.2	8
22	Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans. Frontiers in Immunology, 2021, 12, 700857.	4.8	5
23	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transplantation and Cellular Therapy, 2021, 27, 817-835.	1.2	62
24	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone Marrow Transplantation, 2021, , .	2.4	2
25	Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing. Blood, 2021, 138, 745-745.	1.4	1
26	A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology, 2021, 12, 782152.	4.8	4
27	A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 835-844.	2.0	95
28	Disability Related to Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 772-777.	2.0	16
29	Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 3224-3233.	5.2	20
30	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003â€“2007 Versus 2013â€“2017 Cohorts. Annals of Internal Medicine, 2020, 172, 229.	3.9	157
31	Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 2409-2417.	5.2	14
32	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood, 2020, 136, 1903-1906.	1.4	34
33	How I treat steroid-refractory acute graft-versus-host disease. Blood, 2020, 135, 1630-1638.	1.4	46
34	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Advances, 2020, 4, 40-46.	5.2	11
35	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. Biology of Blood and Marrow Transplantation, 2019, 25, 2468-2473.	2.0	4
36	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e409-e418.	4.6	84

#	Article	IF	Citations
37	Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 1869-1874.	2.0	1
38	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. Biology of Blood and Marrow Transplantation, 2019, 25, 1424-1431.	2.0	14
39	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Advances, 2019, 3, 2764-2777.	5.2	12
40	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. Biology of Blood and Marrow Transplantation, 2019, 25, 451-458.	2.0	19
41	Pathogenic neutrophils in acute GVHD. Blood, 2018, 131, 1774-1775.	1.4	9
42	Educating Radiologists for Self-governance. Academic Radiology, 2018, 25, 540-542.	2.5	0
43	Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 555-562.	2.0	50
44	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. Frontiers in Immunology, 2018, 9, 3061.	4.8	28
45	Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2018, 24, 1692-1698.	2.0	14
46	Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. Blood, 2017, 129, 2693-2701.	1.4	80
47	Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood, 2017, 129, 791-798.	1.4	109
48	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood, 2017, 130, 360-367.	1.4	52
49	Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1257-1263.	2.0	29
50	Association of Plasma CD163 Concentration with De Novoâ€“Onset Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1250-1256.	2.0	38
51	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 405-411.	2.0	11
52	Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nature Communications, 2017, 8, 978.	12.8	58
53	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 10-23.	2.0	20
54	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 211-234.	2.0	328

#	Article	IF	Citations
55	Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease. PLoS ONE, 2017, 12, e0183284.	2.5	13
56	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Antiâ€“T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Diseaseâ€“Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 4003-4011.	1.6	258
57	PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. Journal of Clinical Investigation, 2017, 127, 1960-1977.	8.2	88
58	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. Blood Advances, 2017, 1, 2247-2256.	5.2	15
59	Bone marrow transplantation for CVIDâ€like humoral immune deficiency associated with red cell aplasia. Pediatric Blood and Cancer, 2016, 63, 1856-1859.	1.5	3
60	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood, 2016, 128, 2450-2456.	1.4	32
61	The impact of members of the Society of University Surgeons onÂthe scholarship of American surgery. Surgery, 2016, 160, 47-53.	1.9	6
62	Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2016, 22, 1094-1101.	2.0	33
63	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood, 2016, 127, 160-166.	1.4	43
64	Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood, 2016, 127, 2249-2260.	1.4	74
65	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood, 2016, 127, 1502-1508.	1.4	174
66	The positive association of Association for Academic Surgery membership with academic productivity. Journal of Surgical Research, 2016, 205, 163-168.	1.6	7
67	Impact of clinical fellowships on academic productivity in departments of surgery. Surgery, 2016, 160, 1440-1446.	1.9	6
68	Genetic risk factors for sclerotic graft-versus-host disease. Blood, 2016, 128, 1516-1524.	1.4	18
69	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. Blood, 2016, 127, 3082-3091.	1.4	83
70	Biomarker Panel for Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology, 2016, 34, 2583-2590.	1.6	118
71	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 449-455.	2.0	113
72	Fluticasone, Azithromycin, and Montelukast Treatment forÂNew-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 710-716.	2.0	151

#	Article	IF	Citations
73	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research, 2016, 22, 319-327.	7.0	68
74	How we treat chronic graft-versus-host disease. Blood, 2015, 125, 606-615.	1.4	275
75	Multiâ€centre validation of the prognostic value of the haematopoietic cell transplantationâ€specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2015, 170, 574-583.	2.5	45
76	Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood, 2015, 126, 113-120.	1.4	110
77	Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 2002-2007.	2.0	41
78	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica, 2015, 100, 690-695.	3.5	29
79	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 780-792.	2.0	124
80	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 589-603.	2.0	228
81	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 848-854.	2.0	40
82	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 984-999.	2.0	293
83	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. Biology of Blood and Marrow Transplantation, 2015, 21, 761-767.	2.0	195
84	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 1167-1187.	2.0	182
85	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 1343-1359.	2.0	105
86	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1418-1424.	2.0	62
87	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1679-1686.	2.0	37
88	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 389-401.e1.	2.0	2,636
89	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica, 2014, 99, 1618-1623.	3.5	29
90	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood, 2014, 124, 1363-1371.	1.4	86

#	Article	IF	Citations
91	Assessment of Joint and Fascia Manifestations in Chronic Graftâ€Versusâ€Host Disease. Arthritis and Rheumatology, 2014, 66, 1044-1052.	5.6	50
92	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 337-344.	2.0	76
93	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 3249-3256.	1.6	361
94	Late Cardiovascular Complications after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 794-800.	2.0	84
95	Outcomes of Lung Transplantation after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1169-1175.	2.0	43
96	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood, 2014, 123, 786-793.	1.4	94
97	Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. Haematologica, 2014, 99, 385-391.	3.5	23
98	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood, 2014, 124, 287-295.	1.4	83
99	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood, 2014, 124, 3221-3227.	1.4	92
100	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. Biology of Blood and Marrow Transplantation, 2013, 19, 792-798.	2.0	27
101	A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 1323-1330.	2.0	76
102	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 1530-1538.	1.6	197
103	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood, 2013, 121, 5098-5103.	1.4	93
104	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood, 2013, 121, 2340-2346.	1.4	55
105	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica, 2012, 97, 451-458.	3.5	77
106	Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood, 2012, 119, 5311-5319.	1.4	92
107	Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood, 2012, 120, 2796-2806.	1.4	84
108	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood, 2012, 120, 2545-2552.	1.4	101

#	Article	IF	Citations
109	Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, 1649-1655.	2.0	22
110	Validation of Measurement Scales in Ocular Graft-versus-Host Disease. Ophthalmology, 2012, 119, 487-493.	5.2	83
111	Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, 922-929.	2.0	16
112	Secondary Treatment of Acute Graft-versus-Host Disease: A Critical Review. Biology of Blood and Marrow Transplantation, 2012, 18, 982-988.	2.0	52
113	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1150-1163.	2.0	506
114	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, 1517-1524.	2.0	47
115	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 124-132.	2.0	26
116	A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change. Biology of Blood and Marrow Transplantation, 2011, 17, 1619-1629.	2.0	61
117	Decreased Serum Albumin as a Biomarker for SevereÂAcute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1594-1601.	2.0	60
118	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood, 2011, 117, 3214-3219.	1.4	544
119	Treatment of chronic graft-versus-host disease: Past, present and future. The Korean Journal of Hematology, 2011, 46, 153.	0.7	74
120	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood, 2011, 118, 456-463.	1.4	75
121	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood, 2011, 118, 4242-4249.	1.4	196
122	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics, 2010, 42, 508-514.	21.4	1,132
123	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2010, 28, 1011-1016.	1.6	321
124	HLA-Allele Matched Unrelated Donors Compared toÂHLA-Matched Sibling Donors: Role of Cell Source andÂDisease Risk Category. Biology of Blood and Marrow Transplantation, 2010, 16, 1382-1387.	2.0	60
125	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2010, 363, 2091-2101.	27.0	1,335
126	Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nature Genetics, 2009, 41, 1341-1344.	21.4	91

#	Article	IF	Citations
127	Prognostic Utility of Routine Chimerism Testing at 2 to 6 Months after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 352-359.	2.0	29
128	Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement. Biology of Blood and Marrow Transplantation, 2009, 15, 777-784.	2.0	62
129	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood, 2009, 113, 2888-2894.	1.4	115
130	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 2009, 113, 5074-5082.	1.4	143
131	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood, 2009, 114, 702-708.	1.4	218
132	Front Line Treatment of Chronic Graft versus Host Disease. , 2009, , 124-133.		6
133	Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2008, 14, 1380-1384.	2.0	49
134	Biology of Chronic Graft-versus-Host Disease: Implications for a Future Therapeutic Approach. Keio Journal of Medicine, 2008, 57, 177-183.	1.1	49
135	Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 1016-1021.	2.0	115
136	Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 31-47.	2.0	427
137	Pitfalls in the Design of Clinical Trials for Prevention or Treatment of Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2006, 12, 31-36.	2.0	13
138	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. Biology of Blood and Marrow Transplantation, 2006, 12, 573-584.	2.0	88
139	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266.	2.0	445
140	Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 375-396.	2.0	316
141	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 491-505.	2.0	165
142	An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood, 2006, 108, 749-755.	1.4	112
143	Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.. Blood, 2006, 108, 755-755.	1.4	0
144	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation, 2005, 11, 945-956.	2.0	3,213

#	Article	IF	Citations
145	Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 320-327.	2.0	142
146	Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood, 2004, 104, 3501-3506.	1.4	269
147	Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease. Leukemia and Lymphoma, 2003, 44, 1141-1146.	1.3	25
148	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 2003, 102, 756-762.	1.4	531
149	Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 208-214.	5.6	233
150	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood, 2003, 102, 820-826.	1.4	190
151	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood, 2002, 100, 48-51.	1.4	263
152	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood, 2002, 100, 415-419.	1.4	403
153	Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2001, 7, 384-387.	2.0	98
154	Winning the battle of graft versus host. Nature Medicine, 2000, 6, 18-19.	30.7	11
155	Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood, 2000, 96, 3995-3996.	1.4	122
156	Adherence of adoptively transferred alloreactive Th1 cells in lung: partial dependence on LFA-1 and ICAM-1. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L583-L591.	2.9	23
157	Endothelial Cells of Hematopoietic Origin Make a Significant Contribution to Adult Blood Vessel Formation. Circulation Research, 2000, 87, 728-730.	4.5	507
158	A phase I/II trial of iodine-131â€“tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood, 2000, 96, 2934-2942.	1.4	173
159	Correlation Between Disparity for the Minor Histocompatibility Antigen HA-1 and the Development of Acute Graft-Versus-Host Disease After Allogeneic Marrow Transplantation. Blood, 1999, 94, 2911-2914.	1.4	121
160	Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient. Blood, 1998, 92, 3515-3520.	1.4	442
161	Role of CD28 in Acute Graft-Versus-Host Disease. Blood, 1998, 92, 2963-2970.	1.4	62
162	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. Blood, 1997, 89, 4226-4235.	1.4	358

#	Article	IF	Citations
163	Hematopoietic stem cell transplants from unrelated donors. Immunological Reviews, 1997, 157, 141-151.	6.0	99
164	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. Blood, 1997, 89, 3880-3887.	1.4	3
165	Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: Matching for transplants from related haploidentical donors. Tissue Antigens, 1994, 44, 83-92.	1.0	17
166	Molecular diversity of the HLAâ€C locus in unrelated marrow transplantation. Tissue Antigens, 1994, 44, 93-99.	1.0	49
167	HLAâ€DRB1 frrst domain sequences of two new DR11 alleles and one novel DR4 allele. Tissue Antigens, 1993, 42, 533-535.	1.0	9
168	A pilot study of lowâ€dose cyclosporin for graftâ€versusâ€host prophylaxis in marrow transplantation. British Journal of Haematology, 1992, 80, 49-54.	2.5	35
169	HLAâ€DR molecules enhance signal transduction through the CD3/Ti complex in activated T cells. Tissue Antigens, 1991, 38, 72-77.	1.0	10
170	Polymorphism of HLAâ€DRw52â€associated DRB1 genes as defined by sequenceâ€specific oligonucleotide probe hybridization and sequencing. Tissue Antigens, 1991, 38, 169-177.	1.0	44
171	Signal transduction by HLA class II antigens expressed on activated T cells. European Journal of Immunology, 1991, 21, 123-129.	2.9	44
172	Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies. European Journal of Immunology, 1991, 21, 2121-2131.	2.9	49
173	Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Human Immunology, 1990, 29, 79-91.	2.4	325
174	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. British Journal of Haematology, 1989, 72, 567-572.	2.5	95
175	Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature, 1980, 287, 49-50.	27.8	237
176	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation. , 0, , 365-375.		1
177	Overview of Hematopoietic Cell Transplantation Immunology. , 0, , 129-144.		0